 |
| She noted that only three vaccine developers were given the green light to conduct their Phase 3 clinical trials in the Philippines. (Photo from Manila Bulletin) |
[Asia News Communication = Reporter Reakkana] The Department of Science and Technology (DOST) said Friday, May 7, that three more vaccine developers have applied to conduct coronavirus disease (COVID) vaccine clinical trials in the country. DOST Undersecretary Rowena Cristina Guevara, chief of the Task Group on Vaccine Evaluation and Selection (TG-VES), said the three vaccine developers who expressed intent to conduct clinical trials are all from China, Manila Bulletin reported.
"Our Task Group has received new applications for a clinical trial from Shenzhen Kangtai Biological Products, West China Hospital, and Sichuan University,” she said at the sidelines of DOST Secretary Fortunato “Boy” T. de la Peña’s weekly report on Friday. She noted that only three vaccine developers were given the green light to conduct their Phase 3 clinical trials in the Philippines. These are Clover Pharmaceuticals, and Sinovac Biotech, both from China, and Janssen Pharmaceuticals.
During a public briefing on April 12, DOST Secretary Fortunato “Boy” T. de la Peña said China’s Sinovac Biotech may not pursue its vaccine clinical trials in the country after its SARS-CoV-2 vaccine Vero Cell Inactivated, or the CoronaVac was granted emergency use authorization (EUA) by the Food and Drug Administration (FDA).
